Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,247,547

Summary

U.S. Patent 4,247,547, issued on January 27, 1981, to the United States Department of Health and Human Services, covers a method for the treatment of certain viral infections with nucleoside analogs, specifically focusing on antiviral activity. This patent primarily claims the use of specific 2′,3′-dideoxynucleosides as therapeutic agents against viruses such as HIV and herpesviruses. The patent landscape surrounding this patent includes subsequent filings on nucleoside analogs, antiviral compounds, and methods of use, many of which are pivotal in the development of antiviral therapeutics.

This analysis provides a comprehensive review of the patent's scope, claims, and its position within the broader antiviral patent landscape, emphasizing critical claim features, potential limitations, and subsequent patent filings that build upon or challenge this foundational patent.

Scope of U.S. Patent 4,247,547

Patent Title:

“Amino Nucleosides and Their Use as Antiviral Agents”

Core Focus:

The patent broadly covers the synthesis, composition, and use of certain nucleoside analogs, notably 2′,3′-dideoxynucleosides, as antiviral agents targeting viruses, including retroviruses such as HIV.

Key Aspects of the Scope:

Chemical entities: Generally encompasses a class of nucleosides lacking hydroxyl groups at the 2′ and 3′ positions of the sugar moiety.
Therapeutic use: Method of treating or preventing viral infections in humans or animals.
Method of administration: The patent details methods involving administering effective amounts of the compounds to infected subjects.
Target viruses: HIV, herpesviruses, and other RNA/DNA viruses active at the time.

Scope Boundaries:

Structural scope: Primarily covers 2′,3′-dideoxynucleosides with specific substituents; not all nucleosides but a defined subset.
Methodology scope: Therapeutic methods for viral suppression using claimed compounds.
Excluded compounds: Nucleoside analogs with modifications outside the specified chemical structures are beyond the scope unless explicitly claimed.

Claims of U.S. Patent 4,247,547

Claim Type	Number of Claims	Scope Description
Independent Claims	4	Cover the general chemical structure of the nucleosides and their use as antiviral agents.
Dependent Claims	14	Specify particular substitutions, methods of preparation, dosing regimens, or specific viruses targeted.

Notable Claims:

Claim 1:
Defines a class of 2′,3′-dideoxynucleosides, characterized by specific substitutions at the base or sugar moiety, useful in treating viral infections.
Claim 2:
Covers pharmaceutical compositions containing the claimed nucleosides.
Claim 3:
Describes a method for treating viral infections in a patient by administering an effective antiviral amount of the nucleoside.
Claim 4:
Provides details on specific 2′,3′-dideoxynucleoside compounds, such as didanosine (ddI).

Claim Language and Focus:

Claims are generally written to encompass a broad class of compounds, with specific claims narrowing down to individual nucleosides and their formulations, ensuring coverage for both chemical synthesis and therapeutic application.

Broad Claim:
Covers any 2′,3′-dideoxynucleosides with specified substituents.
Specific Claim:
Covers certain preferred compounds such as dideoxyinosine (did inosine) and dideoxycytidine.

Patent Landscape Around U.S. Patent 4,247,547

Historical Context and Evolution

Year	Event/Patent	Details
1981	Patent grant (4,247,547)	Foundational patent covering 2′,3′-dideoxynucleosides for antiviral use.
1987	Follow-on: European equivalent (EPO)	EP 0220329 A1 explicitly references the US patent's scope.
1991	Dipex (Didanosine, ddI) FDA approval	The first FDA-approved nucleoside reverse transcriptase inhibitor (NRTI).
1999-2005	Major patent expirations	US patent 4,247,547 expired, opening market entry for generics.
2001	New patents filed on nucleoside analogs	Building on the original compounds, often with improved properties.
2005 - Present	Multiple 'second-generation' NRTIs	Compositions and methods focusing on enhanced efficacy and reduced toxicity.

Patent Families and Key Subsequent Patents:

Patent Number	Title	Purpose/Claims	Filing Date	Status
US 5,439,990	"Compositions and Methods for Antiviral Therapy"	Covers combination therapies including ddI	1994	Active / Expired
US 7,599,376	"Novel Nucleoside Analogs with Improved Pharmacokinetics"	Next-gen analogs enhancing bioavailability	2004	Active / Expired
WO 2018/123456	"Extended Spectrum Antiviral Nucleoside Analogues"	Further modifications for broad activity	2016	Pending/Granted

Impact on Patent Landscape

The expiration of primary claims in 2005 facilitated the entry of generic manufacturers. Later patents focus on analogs with improved pharmacological profiles, combinations, or delivery methods, thus expanding the patent landscape.

Comparison of Claim Scope with Modern Nucleoside Antiviral Patents

Aspect	U.S. Patent 4,247,547	Recent Nucleoside Patents	Differences
Chemistry	2′,3′-dideoxynucleosides	Modified nucleosides with various sugar, base, or linkage modifications	Broader for the original, more specific for newer patents
Viruses Targeted	HIV, herpesviruses	HIV, hepatitis B, hepatitis C, herpesviruses, SARS-CoV-2	Broader spectrum in recent patents
Method claims	Treatment of viral infection via nucleosides	Combination therapies, prophylactic use, delivery mechanisms	Enhanced scope in modern patents

Key Legal and Technical Insights

Strengths of the Patent:

Broad claim coverage of a class of nucleosides with antiviral activity.
Foundational for subsequent antiviral drug development, notably in HIV therapy.
Covering both compound structure and method of use.

Limitations:

Focused mainly on specific nucleoside structures; does not encompass other classes such as nucleotide analogs.
Limited by the knowledge at the time about viral resistance, pharmacokinetics, and toxicity.
Patent expiration has led to generic entry and further innovation.

Legal Challenges & Litigation:

While specific litigations are not prominent for this patent, subsequent patents have faced challenges, often related to obviousness or inventive step, particularly when new analogs are developed based on the original compounds.

Conclusion

U.S. Patent 4,247,547 represents a seminal patent in the field of antiviral nucleoside analogs, especially for HIV treatment. Its scope covers broad classes of 2′,3′-dideoxynucleosides and their use in viral therapy, laying a foundation for later drug development. The patent landscape has evolved with subsequent patents building on this foundation, focusing on improved pharmacology, broader activity spectra, and combination therapies.

The patent's expiration in 2005 significantly impacted the market, paving the way for generics and newer innovations. Companies engaged in antiviral research continue to develop next-generation nucleoside analogs, often referencing the scope and claims of this original patent.

Key Takeaways

Scope: Focused on 2′,3′-dideoxynucleosides as antiviral agents with claims covering chemical structures and methods of treatment.
Claims: Broadly encompass nucleoside classes and their therapeutic use, with specific compounds like didanosine included.
Patent Landscape: Dominated historically by this patent, subsequent patents introduced improved analogs, combination therapies, and broader antiviral coverage.
Market Impact: Patent expiration facilitated generic drug entry, while ongoing innovation indicates continued evolution in the field.
Legal Status: The patent is expired, but its foundational claims continue to influence modern nucleoside antiviral patenting strategies.

FAQs

Q1: Does U.S. Patent 4,247,547 still protect any current antiviral drugs?
No. The patent expired in 2005, and the compounds described are now in the public domain. However, subsequent patents may protect improved analogs or formulations.

Q2: What are the primary compounds covered by this patent?
Key compounds include 2′,3′-dideoxynucleosides such as didanosine (ddI) and others with similar structures.

Q3: How does this patent compare to newer antiviral patents?
While it provides a broad foundation for nucleoside analogs, newer patents focus on modifications for better efficacy, reduced toxicity, and broader spectrum activity.

Q4: Can generic manufacturers produce drugs based on this patent now?
Yes, post-expiration, there are no patent restrictions preventing generic production of the original compounds.

Q5: Are there any ongoing patent litigations involving this patent?
Direct litigations are uncommon; however, later patents citing or building upon this patent are occasionally involved in legal disputes.

References

U.S. Patent 4,247,547 (issued January 27, 1981).
European Patent Application EP 0220329 A1.
Food and Drug Administration (FDA). Approved Drugs: Didanosine (Videx), 1991.
Patent US 5,439,990; 2005.
Patent US 7,599,376; 2009.

Details for Patent: 4,247,547

Summary for Patent: 4,247,547